On September 6, 2007, the Centers for Disease Control and Prevention reported that the<unk>  rate in American adolescents, (especially girls, 10 to 24 years old), increased 8% (2003 to 2004), the largest jump in 15 years, to 4,599<unk> s in Americans ages 10 to 24 in 2004, from 4,232 in 2003, giving a<unk>  rate of 7.32 per 100,000 people that age. The rate previously dropped to 6.78 per 100,000 in 2003 from 9.48 per 100,000 in 1990. Jon Jureidini, a critic of this study, says that the US "2004<unk>  figures were compared simplistically with the previous year, rather than examining the change in trends over several years". It has been noted that the pitfalls of such attempts to infer a trend using just two data points (years 2003 and 2004) are further demonstrated by the fact that, according to the new epidemiological data, the<unk>  rate in 2005 in children and adolescents actually declined despite the continuing decrease of SSRI prescriptions. "It is<unk> y to draw conclusions from limited ecologic analyses of isolated year-to-year fluctuations in<unk> prescriptions and<unk> s. One promising epidemiological approach involves examining the associations between trends in psychotropic medication use and<unk>  over time across a large number of small geographic regions. Until the results of more detailed analyses are known, prudence dictates deferring judgment concerning the public health effects of the FDA warnings." Subsequent follow-up studies have supported the hypothesis that<unk> drugs reduce<unk> <unk> .
Antidepressants and suicide risk
Treatments for PTSD
Alcohol use and sleep
Long-term effects of cannabis
Alcohol and cardiovascular disease
Pharmacology of antidepressants
Clinical descriptions of chronic fatigue syndrome
Long-term effects of alcohol